Dermata Therapeutics, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
This is a routine quarterly filing (10-Q) for the period ended June 30, 2026, filed August 11, 2026. The filing document index contains standard SEC exhibits (certifications, XBRL data files) but the actual financial statements and MD&A text are not provided in this header extract. No specific financial metrics, deal announcements, or material events are disclosed in the available filing metadata.
Why this rating
Routine quarterly disclosure with no disclosed material events; company scale $3.1M makes standard filing immaterial without substantive news
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.